2022
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis
2021
PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis
Lee J, Chaft J, Nicholas A, Patterson A, Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, Owen D, Finley D, Mcnamee C, Blasberg J, Garon E, Mitchell J, Doebele R, Baciewicz F, Nagasaka M, Pass H, Schulze K, Phan S, Johnson A, Bunn P, Johnson B, Kris M, Kwiatkowski D, Wistuba I, Carbone D, Rusch V. PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis. Journal Of Thoracic Oncology 2021, 16: s59-s61. DOI: 10.1016/j.jtho.2021.01.320.Peer-Reviewed Original ResearchThe Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical And Research Reports 2021, 2: 100143. PMID: 34590002, PMCID: PMC8474228, DOI: 10.1016/j.jtocrr.2021.100143.Peer-Reviewed Original ResearchStage I NSCLCWedge resectionSurveillance EpidemiologyMortality riskHigh riskSurvival advantageLife expectancyNational Cancer Institute's Surveillance EpidemiologyEnd Results-MedicareTreatment-naive patientsEarly-stage NSCLCRetrospective cohort studySuperior local controlShort life expectancyLife expectancy decreasesPerioperative complicationsCohort studyComorbid conditionsLung parenchymaLobectomyCox modelReasonable optionPatientsNSCLCLocal control
2019
P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial
Lee J, Chaft J, Nicholas A, Patterson G, Waqar S, Toloza E, Haura E, Raz D, Reckamp K, Merritt R, Owen D, Finley D, Mcnamee C, Blasberg J, Garon E, Mitchell J, Doebele R, Baciewicz F, Nagasaka M, Pass H, Johnson A, Phan S, Schulze K, Bunn P, Johnson B, Kris M, Kwiatkowski D, Wistuba I, Carbone D, Rusch V. P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial. Journal Of Thoracic Oncology 2019, 14: s744. DOI: 10.1016/j.jtho.2019.08.1593.Peer-Reviewed Original Research
2012
Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population
Joseph S, Harrington R, Walter D, Goldberg JD, Li X, Beck A, Litton T, Hirsch N, Blasberg J, Slomiany M, Rom W, Pass H, Donington J. Plasma osteopontin velocity differentiates lung cancers from controls in a CT screening population. Cancer Biomarkers 2012, 12: 177-184. PMID: 23568008, PMCID: PMC3746829, DOI: 10.3233/cbm-130306.Peer-Reviewed Original ResearchConceptsIncident cancerPlasma osteopontinNon-small cell lung cancer careLung cancer careCase-control studySerial plasmaNSCLC patientsCT screeningSurveillance intervalsCancer careLung cancerPlasma levelsWilcoxon Signed Rank TestDisease statusCancerSigned Rank TestBenign nodulesSecreted phosphoproteinCTRank testOsteopontinEarly evidenceNSCLCPatientsNSCLCs
2010
Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer
Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. Reduction of Elevated Plasma Osteopontin Levels With Resection of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2010, 28: 936-941. PMID: 20085934, PMCID: PMC2834433, DOI: 10.1200/jco.2009.25.5711.Peer-Reviewed Original ResearchConceptsEarly-stage NSCLCPlasma osteopontin levelsPlasma OPN levelsOPN levelsEnzyme-linked immunosorbent assayPlasma OPNOsteopontin levelsWeeks postsurgeryElevated Plasma Osteopontin LevelsCell lung cancer correlatesUse of thoracotomyCell lung cancerLung cancer correlatesCancer-free smokersResectable NSCLCPerioperative eventsTumor characteristicsPresurgery levelsRecurrence rateValidation cohortLung cancerCancer correlatesTherapeutic responseNSCLCIndependent cohort